Seeking Alpha·United States·Tuesday, September 22, 2026 at 11:11 PM

Aytu outlines $49M-$54M FY27 operating expense plan as it targets 66%-67% gross margin in Q4 FY27

Translate

SA Transcript Insights Editor

Earnings Call Insights: Aytu BioPharma (AYTU) Q4 fiscal 2026

Management view

“We finished fiscal 2026 with an encouraging fourth quarter as EXXUA continued to build, our ADHD business performed better than anticipated, and Aytu returned to positive adjusted EBITDA.” (CEO & Director Joshua Disbrow)

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

View the original on Seeking Alpha →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.